Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies
R Buhl, E Derom, G Ferguson, F Maltais, E Pizzichini, J Reid, H Watz, L Groenke, A Hamilton, K Tetzlaff, L Korducki, H Huisman, S Waitere-Wijker, E Bateman · Pneumologie · 2015 · Heft 02
Bibliografische Angaben
Zusammenfassung
Introduction: Tiotropium (T), a once-daily long-acting muscarinic antagonist, is a well-established first-line maintenance treatment in chronic obstructive pulmonary disease (COPD); olodaterol (O) is a once-daily long-acting ß2-agonist that has recently gained approval in several countries. Two Phase III replicate pivotal studies assessed the efficacy and safety of fixed-dose combinations of T and O (T+O) delivered via Respimat Soft Mist inhaler in patients with GOLD Stage 2 – 4 COPD. Methods: Two 52-week, double-blind, parallel-group studies randomised 5162 patients to O 5 µg, T 2.5 µg, T 5 µg, T+O 2.5/5 µg or…
